The phase 2 type 2 diabetes trial, as Rosenstock and colleagues reported it

Published 24 October 2026 · REVIVE LAB UAE Research Desk · 5 min read
Rosenstock and colleagues reported a 36-week, randomised, double-blind phase 2 trial in 281 adults with type 2 diabetes in The Lancet in 2023, comparing several retatrutide groups against both placebo and dulaglutide. The primary endpoint was change in glycated haemoglobin at 24 weeks.

Design

Adults with type 2 diabetes managed by diet and exercise alone or on a stable dose of metformin were randomised to placebo, to a long-acting GLP-1 receptor agonist already in clinical use as the active comparator, or to one of several retatrutide groups. Treatment ran for 36 weeks.

Including an active comparator is what distinguishes this trial from the obesity study: it allowed the compound to be set against an existing therapy rather than against placebo alone.

What was reported

Reductions in glycated haemoglobin at 24 and 36 weeks were dose-dependent and, in the higher groups, exceeded those seen with the comparator. Body weight fell in a dose-dependent manner alongside.

Adverse events were predominantly gastrointestinal, were mild to moderate in most cases, and were more frequent at higher doses and during escalation. The authors reported no severe hypoglycaemia in the retatrutide groups.

What follows and what does not

A phase 2 trial in 281 people establishes dose-response and supports a phase 3 programme; it does not establish long-term safety, and 36 weeks is not a durability study. The paper is specific about this.

Head-to-head against one comparator in one trial is also not a class comparison, and the authors do not present it as one.

Supply

Retatrutide is supplied by REVIVE LAB UAE as an investigational research material for laboratory use only, with identity by mass spectrometry and purity by HPLC for the batch. It is not approved for any use anywhere, and no dosing, administration or protocol guidance is provided.

What it costs

FormatStrengthPriceAvailability
Retatrutide Pack20 mgAED 1010In stock

Delivery is AED 40 flat and free on orders over AED 700. Payment is cash on delivery anywhere in the UAE, or USDT (TRC20) in advance, which takes 5% off the order total.

Frequently asked

Design?

Adults with type 2 diabetes managed by diet and exercise alone or on a stable dose of metformin were randomised to placebo, to a long-acting GLP-1 receptor agonist already in clinical use as the active comparator, or to one of several retatrutide groups. Treatment ran for 36 weeks.

Does REVIVE LAB UAE provide dosing guidance?

No. REVIVE LAB UAE supplies research materials and provides no dosing, administration or protocol guidance of any kind. Every product is sold for laboratory research use only and is not for human or veterinary consumption.

How fast is delivery in the UAE?

Stock is held in Dubai. An order confirmed before 4 PM Dubai time is dispatched the same working day, reaching Dubai and Abu Dhabi the same day and the remaining emirates within 24 hours. Delivery is AED 40 flat and free over AED 700.

Retatrutide Pack — in stock, dispatched from Dubai
HPLC-verified, lot certificate on every carton, 24-hour delivery nationwide. Browse the catalogue → All peptides UAE

Related reading

Supplied for laboratory research use only. Not for human or veterinary consumption. REVIVE LAB UAE provides no dosing, administration or protocol guidance.